Compare JPMorgan Ultra Short Income ETF (JPST) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Pfizer Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.37B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 3.8× JPMorgan Ultra Short Income ETF's market cap, and Pfizer Inc pays a 6.14% dividend while JPMorgan Ultra Short Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 46 Days and Pfizer Inc for 158 Days on average.
| JPST | PFE | |
|---|---|---|
Market Cap | $42.37B | $159.59B |
Volume | 7,889,185 | 30,937,010 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $29.02 |
52-Week Low | $50.22 | $23.67 |
Typical Hold Time | 46 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPST trades at $50.27, up 0.04% with a bearish technical signal from moving averages. The ETF shows neutral oscillators like RSI near 35, while recent news highlights institutional selling and mixed sentiment on its yield competitiveness. Dividend payments of $0.17 are scheduled through October 2026, but key financial ratios are unavailable for fundamental assessment.
Outlook remains cautious due to technical weakness and underperformance concerns cited by analysts. Risks include interest rate sensitivity and expense ratios, but demand for ultra-short income ETFs amid market volatility offers stability. Investors should weigh yield against peer comparisons and fee structures.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
